4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Okay, well, thank you, everyone, for joining us. We are here with 4DMT, Kristian Humer, CFO; and Chris Simms, CCO and CBO. Maybe you could start with an overview of your Directed Evolution gene therapy platform, your pipeline progress, and your 12-month catalyst path.
Questions & Answers
Yeah. Hey, great to be here. Thanks for the opportunity. I'm happy to start with that, and maybe Christian can fill the details in our catalyst that are coming up for the next 12 months.
So first of all, 4DMT, we're a next-generation gene therapy company, platform company. We have a number of programs in development, but the program that's taken the majority of our focus right now is a program, we call it 4D-150, and that's a gene therapy that we're studying for the treatment of wet AMD. So our wet AMD 4FRONT-1 and 4FRONT-2 Phase 3 trials are underway right now. So that's our leading program.
We hope to start our trial for DME, so diabetic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
